SuO-Val-Cit-PAB-MMAE (CAT#: ADC-S-077)

Linker-Toxin SET, this set is made by MMAE conjugated to the lysosomally cleavable SuO-Val-Cit-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Product Information

Description
Linker-Toxin SET, this set is made by MMAE conjugated to the lysosomally cleavable SuO-Val-Cit-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Molecular Weight
1264.51

Purity
95%

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-S-077. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Creative Biolabs' SuO-Val-Cit-PAB-MMAE proved to be a highly effective ADC payload. The compound's stability and specific action on tumor cells greatly improved our targeted therapy experiments.

Excellent

We've had consistent success with Creative Biolabs' SuO-Val-Cit-PAB-MMAE. The compound provided effective and controlled cytotoxicity in our experiments, making it a top choice for our ADC development.

Excellent

Creative Biolabs' SuO-Val-Cit-PAB-MMAE has been a reliable asset in our research. The linker-drug combination ensured targeted action, resulting in enhanced cytotoxicity in our cancer cell assays.

Excellent

Using SuO-Val-Cit-PAB-MMAE from Creative Biolabs yielded impressive results in our lab. Its controlled drug release and potency were crucial for effective antibody-drug conjugate design and performance.

Excellent

SuO-Val-Cit-PAB-MMAE from Creative Biolabs delivered outstanding performance in our ADC research. The linker-drug system showed excellent stability and targeted cytotoxicity, enhancing the precision of our cancer cell studies.

Q: 1: What is SuO-Val-Cit-PAB-MMAE used for in research?
A: SuO-Val-Cit-PAB-MMAE is a potent cytotoxic payload used in antibody-drug conjugates (ADCs) for cancer therapy. It is linked to antibodies that target cancer cells, delivering the MMAE toxin to induce cell death.
Q: 2: How does SuO-Val-Cit-PAB-MMAE function in ADCs?
A: The Val-Cit peptide linker in SuO-Val-Cit-PAB-MMAE is cleaved by proteases in cancer cells, releasing MMAE (monomethyl auristatin E) to disrupt microtubules and induce apoptosis.
Q: 3: What type of cancer therapies can SuO-Val-Cit-PAB-MMAE be integrated into?
A: SuO-Val-Cit-PAB-MMAE is primarily used in antibody-drug conjugates (ADCs) for targeted cancer therapies. It is effective in treating cancers with specific surface markers, such as lymphoma and breast cancer.
Q: 4: How does SuO-Val-Cit-PAB-MMAE compare to other MMAE-based ADCs?
A: SuO-Val-Cit-PAB-MMAE offers high potency with a cleavable Val-Cit linker, similar to other MMAE-based ADCs, but Creative Biolabs' version ensures high purity and optimized conjugation efficiency for research applications.
Q: 5: What cell lines are suitable for testing SuO-Val-Cit-PAB-MMAE?
A: SuO-Val-Cit-PAB-MMAE is commonly tested on cancer cell lines that express specific surface markers targeted by ADCs, such as HER2-positive or CD30-positive cell lines in cancer research.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.